Literature DB >> 16707190

SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes.

Yuichiro Yamada1, Kazuhito Fukuda, Shimpei Fujimoto, Masaya Hosokawa, Katsushi Tsukiyama, Kazuaki Nagashima, Mitsuo Fukushima, Haruhiko Suzuki, Kentaro Toyoda, Mariko Sassa, Shogo Funakoshi, Nobuya Inagaki, Ataru Taniguchi, T Shun Sato, Shinichi Matsumoto, Koichi Tanaka, Yutaka Seino.   

Abstract

Evaluation of a patient's pancreatic beta-cell function is important in both diagnosis and treatment of diabetes. We sought to determine beta-cell function with a single sampling of blood. Examination of fasting blood glucose (F-BG, mM) and C-peptide (F-CPR, nM) levels in seven post-islet-transplanted states of four patients revealed a linear relationship between F-BG and F-CPR. Assuming that normal subjects aged <40 years have 100% pancreatic beta-cell function, we developed the secretory units of islets in transplantation (SUIT) as an index of beta-cell function by the formula: 250 x F-CPR/(F-BG-3.43). The SUIT index was correlated with the stimulated C-peptide levels not only in islet-transplanted patients (R2 = 0.68, P < 0.05) but also in type 2 patients (R2 = 0.34, P < 0.001). Since the SUIT index can be calculated from data obtained at a single fasting blood sampling and predict the pancreatic beta-cell function, the formula may be a useful tool in clinical management of diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707190     DOI: 10.1016/j.diabres.2006.03.030

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  24 in total

Review 1.  SUITO index for evaluation of clinical islet transplantation.

Authors:  Morihito Takita; Shinichi Matusmoto
Journal:  Cell Transplant       Date:  2012       Impact factor: 4.064

2.  Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome.

Authors:  Manabu Kondo; Katsuya Tanabe; Kikuko Amo-Shiinoki; Masayuki Hatanaka; Tsukasa Morii; Harumi Takahashi; Susumu Seino; Yuichiro Yamada; Yukio Tanizawa
Journal:  Diabetologia       Date:  2018-07-28       Impact factor: 10.122

3.  Improvement of pancreatic islet cell isolation for transplantation.

Authors:  Shinichi Matsumoto; Hirofumi Noguchi; Bashoo Naziruddin; Nicolas Onaca; Andrew Jackson; Hatanaka Nobuyo; Okitsu Teru; Kobayashi Naoya; Göran Klintmalm; Marlon Levy
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-10

4.  Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides.

Authors:  Tsuyoshi Tanaka; Hiroyuki Goto; Rika Araki; Mika Yamamoto; Takashi Tanaka; Ryoko Fujiwara; Kazuya Murata
Journal:  J Diabetes Investig       Date:  2013-09-24       Impact factor: 4.232

5.  Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.

Authors:  Shogo Funakoshi; Shimpei Fujimoto; Akihiro Hamasaki; Hideya Fujiwara; Yoshihito Fujita; Kaori Ikeda; Shiho Takahara; Kazuaki Nagashima; Masaya Hosokawa; Yutaka Seino; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2011-08-02       Impact factor: 4.232

6.  Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus.

Authors:  Akira Kubota; Ikuro Matsuba; Tatsuhiko Saito; Koichiro Nabe; Yutaka Seino
Journal:  J Diabetes Investig       Date:  2011-10-07       Impact factor: 4.232

7.  Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients.

Authors:  Keiko Fujisawa; Tetsuyuki Yasuda; Hideaki Kaneto; Naoto Katakami; Mayumi Tsuji; Fumiyo Kubo; Shugo Sasaki; Kazuyuki Miyashita; Toyoko Naka; Ryuuichi Kasami; Akio Kuroda; Munehide Matsuhisa; Iichiro Shimomura
Journal:  J Diabetes Investig       Date:  2013-11-28       Impact factor: 4.232

8.  Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.

Authors:  Tae Jung Oh; Hye Seung Jung; Jae Hyun Bae; Yeong Gi Kim; Kyeong Seon Park; Young Min Cho; Kyong Soo Park; Seong Yeon Kim
Journal:  J Korean Med Sci       Date:  2013-06-03       Impact factor: 2.153

9.  Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.

Authors:  Rika Ito; Tomoyasu Fukui; Toshiyuki Hayashi; Anna Osamura; Makoto Ohara; Noriko Hara; Akiko Higuchi; Takeshi Yamamoto; Tsutomu Hirano
Journal:  Drugs R D       Date:  2015-09

Review 10.  Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.

Authors:  Takaaki Murakami; Hiroyuki Fujimoto; Nobuya Inagaki
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.